Zydus Lifesciences on Monday said it has received approval from the US health regulator to market a drug for the treatment of irritable bowel syndrome with diarrhoea in adults.
The company has received tentative approval from the US Food and Drug Administration (USFDA) for Rifaximin Tablets (550 mg), the drug manufacturing firm said in a regulatory filing.
Rifaximin tablets are indicated for the treatment of irritable bowel syndrome with diarrhoea ( IBS-D) in adults.
As per the IQVIA MAT March sales data, Rifaximin tablets had an annual sales of USD 2,672.9 million in the US.
Shares of Zydus Lifesciences were trading at Rs 926.05 apiece, 0.41 per cent down from previous close, on BSE.
The company has received tentative approval from the US Food and Drug Administration (USFDA) for Rifaximin Tablets (550 mg), the drug manufacturing firm said in a regulatory filing.
Rifaximin tablets are indicated for the treatment of irritable bowel syndrome with diarrhoea ( IBS-D) in adults.
As per the IQVIA MAT March sales data, Rifaximin tablets had an annual sales of USD 2,672.9 million in the US.
Shares of Zydus Lifesciences were trading at Rs 926.05 apiece, 0.41 per cent down from previous close, on BSE.
You may also like
Found & released: 3 Indians missing in Iran rescued by cops in Tehran; all you need to know
Baked beans will taste way better with 'delicious flavour' if you add 1 ingredient
IPL 2025 Prize Money: How much money did RCB get for becoming the IPL champion? PBKS and Mumbai Indians also won the lottery..
RCB win IPL 2025: Bengaluru, get ready to celebrate! Kohli, ABD, Gayle, and team coming home for royal homecoming bash
IPL 2025 Final: Kohli made RCB champion by playing the biggest innings in the final, reminded of T20 World Cup..
